IPD — ImpediMed Income Statement
0.000.00%
Last trade - 00:00
- AU$178.05m
- AU$142.42m
- AU$11.34m
- 56
- 21
- 47
- 39
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.16 | 5.74 | 8.41 | 10.6 | 11.3 |
Cost of Revenue | |||||
Gross Profit | 2.9 | 4.06 | 6.81 | 8.86 | 9.8 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 28.1 | 27.1 | 29.1 | 30.4 | 31.8 |
Operating Profit | -23.9 | -21.3 | -20.7 | -19.8 | -20.5 |
Net Income Before Taxes | -23.9 | -21.3 | -20.7 | -19.8 | -20.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24 | -21.4 | -20.7 | -19.9 | -20.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -24.1 | -21.4 | -20.7 | -19.9 | -20.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.1 | -21.4 | -20.7 | -19.9 | -20.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.06 | -0.038 | -0.018 | -0.012 | -0.011 |